Ribon Therapeutics
mono-PARP Inhibitors

Ribon is pioneering the development of first-in-class therapeutics targeting enzyme families that are activated under cellular stress conditions. Ribon is exploring novel areas of disease biology and use their expertise in drug discovery to develop new and effective treatments for patients with high unmet need. Their focus on gaining a deep understanding of disease biology and unexplored enzyme families allows them to make well-informed decisions as to which targets are best suited for drug discovery.


University
Massachusetts Institute of Technology
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website